Takemasa Tsuji to Ovarian Neoplasms
This is a "connection" page, showing publications Takemasa Tsuji has written about Ovarian Neoplasms.
Connection Strength
2.479
-
Tissue residency of memory CD8+ T cells matters in shaping immunogenicity of ovarian cancer. Cancer Cell. 2022 05 09; 40(5):452-454.
Score: 0.533
-
Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer. Oncoimmunology. 2022; 11(1):2020983.
Score: 0.521
-
Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. PLoS One. 2014; 9(11):e111586.
Score: 0.317
-
BiTE secretion by adoptively transferred stem-like T cells improves FRa+ ovarian cancer control. J Immunother Cancer. 2023 06; 11(6).
Score: 0.144
-
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responses. Sci Transl Med. 2022 03 16; 14(636):eabg8402.
Score: 0.132
-
CXCR6 by increasing retention of memory CD8+ T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer. J Immunother Cancer. 2021 10; 9(10).
Score: 0.128
-
IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells via Aryl Hydrocarbon Receptor Activation. Front Immunol. 2021; 12:678999.
Score: 0.124
-
HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecol Oncol. 2016 07; 142(1):158-162.
Score: 0.088
-
Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep. 2015 Oct 08; 5:14896.
Score: 0.084
-
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 2014; 9(8):e104099.
Score: 0.078
-
Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer Immunol Res. 2014 Jan; 2(1):37-49.
Score: 0.075
-
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012 Dec 01; 18(23):6497-508.
Score: 0.069
-
Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol. 2012 Apr 15; 188(8):3851-8.
Score: 0.066
-
Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors. PLoS One. 2011; 6(8):e23651.
Score: 0.063
-
Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010 Apr 27; 107(17):7875-80.
Score: 0.058